Positioned for the expanding cannabis market

Independent Investment Research

Independent Investment Research

Creso Pharma Limited  will develop, register and commercialise food grade and medicinal grade cannabis, initially supplying food supplements for animals, entering the human food supplement market in the short term, and later supplying medicinal cannabis based products for chronically ill patients.  Governments are progressively legalising the use of medicinal cannabis with 17 countries having  decriminalised medicinal cannabis.  An investment in Creso Pharma Ltd is considered speculative at this stage, based on the company’s low revenue base and the competitive environment. Independent Investment Research expects the company’s strong management, global strategies and low capital cost business model will provide the company with significant competitive advantages.      At this early stage we have  not attributed a price target.

1 stock mentioned

Independent Investment Research
Independent Investment Research
Independent Investment Research

Independent Investment Research, “IIR”, is an independent investment research house based in Australia and the United States. IIR specialises in independent research in small/ micro cap equities across sectors and managed investment ratings both...

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.


Please sign in to comment on this wire.

trending on livewire
Get the best of Livewire by signing up to our popular daily newsletter